国药现代(600420.SH)：法莫替丁注射液通过仿制药质量和疗效一致性评价

Core Viewpoint - The company, China National Pharmaceutical Group Modern (600420.SH), announced that its wholly-owned subsidiary, China National Pharmaceutical Group Rongsheng Pharmaceutical Co., Ltd., received approval from the National Medical Products Administration for the supplemental application of Famotidine injection, which has passed the consistency evaluation of generic drug quality and efficacy [1]. Group 1 - The approval allows Famotidine injection to be used for treating upper gastrointestinal bleeding caused by various reasons, excluding tumors and esophageal or gastric variceal bleeding [1]. - Famotidine is classified as a histamine H2 receptor antagonist and is primarily used for conditions related to mucosal erosion in the stomach and duodenum [1].